Study details
Enrolling now
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Milton S. Hershey Medical Center
NCT IDNCT04414514ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
24
Study length
about 5.3 years
Ages
12+
Locations
1 site in PA
What this study is about
This trial is testing a new treatment called ruxolitinib 1.5% cream applied directly to the skin for hidradenitis suppurativa (HS). The goal is to see if this topical treatment can reduce HS symptoms and inflammation, as well as analyze skin samples from participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ruxolitinib 1.5% Cream
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
topical
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
topical